Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02769520 · ClinicalTrials.gov registry record · Phase 2
Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck
A Phase 2 study of Squamous Cell Carcinoma of the Head and Neck, sponsored by Assuntina G. Sacco, MD.
- Active
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 3
- Study locations
NCT02769520 is a Phase 2 study of Squamous Cell Carcinoma of the Head and Neck that is active but no longer recruiting, run by Assuntina G. Sacco, MD. The registered enrollment target is 27 participants, below the 145-participant average among 29 other Squamous Cell Carcinoma of the Head and Neck trials with a reported enrollment target (81% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT02769520, a Phase 2 study of Squamous Cell Carcinoma of the Head and Neck, is active but no longer recruiting, sponsored by Assuntina G. Sacco, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine whether pembrolizumab, when given after salvage surgery, is effective in increasing the time a person with squamous cell cancer of the head and neck remains disease-free following locoregional disease recurrence.
Conditions Studied
Interventions
- DRUG Pembrolizumab
Study Locations (3)
California
- UCSD Moores Cancer Center - La Jolla
- University of California San Francisco - San Francisco
- University of California Los Angeles - Torrance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2016-07-06 |
| Est. Completion | 2026-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02769520
The ClinicalTrials.gov registry entry for NCT02769520 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 145-participant average among 29 other Squamous Cell Carcinoma of the Head and Neck trials with a reported enrollment target (81% lower). The listed sponsor is Assuntina G. Sacco, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Squamous Cell Carcinoma of the Head and Neck appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT02769520 reports 3 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02769520 about?
NCT02769520 is a clinical study titled "Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck". The purpose of this study is to determine whether pembrolizumab, when given after salvage surgery, is effective in increasing the time a person with squamous cell cancer of the head and neck remains disease-free following locoregional disease recurrence.
What is the current status of trial NCT02769520?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2016-07-06. Estimated completion is 2026-04.
What conditions does trial NCT02769520 study?
This clinical trial studies the following conditions: Squamous Cell Carcinoma of the Head and Neck.
What interventions are being tested in trial NCT02769520?
The interventions under investigation include: Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT02769520?
This trial is sponsored by Assuntina G. Sacco, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02769520 being conducted?
This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Squamous Cell Carcinoma of the Head and Neck
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
RECRUITING · Phase 2
-
Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
RECRUITING · Phase 2
-
A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study
ACTIVE NOT RECRUITING · Phase 2
-
Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN
ACTIVE NOT RECRUITING · Phase 2
-
Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC
ACTIVE NOT RECRUITING · Phase 2
-
Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.